Home・Akcijų sąrašas・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Uždarymo kaina

4.28 -3.39

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.15

Max

4.32

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-136K -35M
Pelnas, tenkantis vienai akcijai	-0.503
Darbuotojai	106
EBITDA	2.2M -35M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+63.82% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	62M 357M
Ankstesnė atidarymo kaina	7.67
Ankstesnė uždarymo kaina	4.28

Zentalis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-24 23:56; UTC

Fox Corp shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains stable within its one-month trading range.

2026-07-24 23:56; UTC

Lumen Technologies Inc shares are higher in after-market trading, continuing fluctuations despite a broader trend of declines over the past month. No specific news identified.

2026-07-24 23:56; UTC

Correlated Moves

State Street Corp shares are lower in after-market trading, reflecting broader market dynamics amid turmoil in the bond markets and sector trends.

2026-07-24 23:56; UTC

Wingstop Inc. shares are higher in after-market trading, recovering from an earlier dip. The stock remains near the lower end of its one-month range.

2026-07-24 23:56; UTC

Cracker Barrel Old Country Store shares are lower in after-market hours. No specific news was identified to explain the decline amid broader market conditions.

2026-07-24 23:56; UTC

Carpenter Technology Corp shares are lower in after-market trading, reflecting broader market trends amid rising concerns in the bond markets.

2026-07-24 23:56; UTC

CMS Energy shares are higher in after-market trading following a slight pullback earlier in the session. The stock has advanced since Friday's close.

2026-07-24 23:56; UTC

DocuSign Inc shares are lower in after-market hours, reflecting a slight decline since Friday's close amid narrow trading fluctuations and no specific news.

2026-07-24 23:56; UTC

JD.Com shares were lower in after-market trading, despite briefly peaking shortly after market open. The stock remains near the upper end of its one-month range.

2026-07-24 23:56; UTC

Correlated Moves

Ares Capital Corp shares declined slightly in after-market trading, reflecting broader financial sector trends amid turmoil in bond markets and rising spreads.

2026-07-24 23:56; UTC

Correlated Moves

ON Semiconductor shares are higher in after-market trading, tracking MACOM's advance. The stock remains near the lower end of its one-month range.

2026-07-24 23:56; UTC

Aptiv PLC shares are trading higher in after-market hours, remaining near the lower end of their one-month trading range. No specific news was identified.

2026-07-24 23:56; UTC

The iShares MSCI South Korea ETF is trading lower in after-market hours, continuing a decline since Friday's close. No specific news was identified.

2026-07-24 23:52; UTC

S&P/Case-Shiller Home Price Index Set to Show 5.2% Increase Amid Mixed Economic Sentiment and Rising Inflation Concerns

2026-07-24 23:52; UTC

South Africa's Upcoming Balance of Trade Data Sparks Caution Amid First Trade Deficit and Global Supply Chain Tensions.

2026-07-24 23:51; UTC

UnitedHealth Group Inc shares are lower in after-market hours, continuing a decline since Friday's close amid broader market trends. No specific news was identified.

2026-07-24 23:51; UTC

Wendy's Co shares are higher in after-market hours, continuing an upward trend from earlier in the session, despite no specific news driving the move.

2026-07-24 23:51; UTC

Pilgrim's Pride Corp shares are higher in after-market trading, continuing gains from Friday's close and nearing the upper end of their one-month trading range.

2026-07-24 23:51; UTC

Axon Enterprise Inc shares are trading lower in after-market hours, reaching a session low amid broader turmoil in bond markets affecting credit investors.

2026-07-24 23:51; UTC

Clear Secure Inc shares are higher in after-market trading, recovering from an initial dip. The stock remains near the lower end of its one-month range.

2026-07-24 23:51; UTC

indie Semiconductor Inc. shares were roughly flat in after-market hours, following four consecutive daily declines amid ongoing market challenges.

2026-07-24 23:51; UTC

Howmet Aerospace Inc shares are higher in after-market trading, continuing a trend of five consecutive sessions of gains. No specific news was identified for the move.

2026-07-24 23:51; UTC

Trimble Inc shares are higher in after-market trading, showing resilience despite challenging macroeconomic conditions and no specific company news identified.

2026-07-24 23:51; UTC

Constellation Brands Inc shares are higher in after-market hours, reflecting modest gains since Friday's close despite broader bond market turmoil.

2026-07-24 23:51; UTC

East West Bancorp Inc shares are higher in after-market trading, reflecting notable strength since Friday's close, with no specific news identified.

2026-07-24 23:51; UTC

U.S. equity indices remain flat as investors weigh mixed earnings, geopolitical tensions, and a surprising drop in jobless claims amidst rising oil prices.

2026-07-24 23:51; UTC

Global equity markets show mixed performance as European indices rise on positive economic data, while Asian markets decline amid geopolitical tensions and rising oil prices.

2026-07-24 23:51; UTC

European equity indices rebound on strong PMI data, while Asian markets decline amid rising oil prices and geopolitical tensions.

2026-07-24 23:51; UTC

Asian equity markets decline amid rising oil prices and geopolitical tensions, while Germany's DAX rises; U.S. stocks remain flat as investors await key economic data.

2026-07-24 23:51; UTC

Axsome Therapeutics Inc shares are lower in after-market hours, reflecting a notable decline since Friday's close, with no specific news identified.

Akcijų palyginimas

Kainos pokytis

Zentalis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

63.82% į viršų

12 mėnesių prognozė

Vidutinis 7.29 USD 63.82%

Aukščiausias 11 USD

Žemiausias 4 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zentalis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Zentalis Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.